Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Adma Biologics (ADMA) Shares Outstanding (Diluted Average) (2020 - 2025)

Adma Biologics (ADMA) has disclosed Shares Outstanding (Diluted Average) for 6 consecutive years, with $244.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding (Diluted Average) rose 0.64% year-over-year to $244.9 million, compared with a TTM value of $244.9 million through Dec 2025, up 0.64%, and an annual FY2025 reading of $244.9 million, up 0.64% over the prior year.
  • Shares Outstanding (Diluted Average) was $244.9 million for Q4 2025 at Adma Biologics, roughly flat from $245.5 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $248.6 million in Q2 2025 and bottomed at $115.7 million in Q1 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $207.6 million, with a median of $223.1 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Diluted Average) skyrocketed 69.35% in 2022, then grew 0.28% in 2025.
  • Year by year, Shares Outstanding (Diluted Average) stood at $139.6 million in 2021, then soared by 41.77% to $197.9 million in 2022, then grew by 13.19% to $224.0 million in 2023, then grew by 8.65% to $243.3 million in 2024, then increased by 0.64% to $244.9 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for ADMA at $244.9 million in Q4 2025, $245.5 million in Q3 2025, and $248.6 million in Q2 2025.